A number of equities analysts have recently commented on MRK shares.

Source: https://www.americanbankingnews.com/2023/03/29/bedrijfstakpensioenfonds-voor-de-media-pno-decreases-stake-in-merck-co-inc-nysemrk.html

A number of institutional investors have recently modified their holdings of MRK.

Source: https://www.etfdailynews.com/2023/10/15/morgan-stanley-trims-merck-co-inc-nysemrk-target-price-to-115-00/

A number of other hedge funds have also added to or reduced their stakes in MRK.

Source: https://www.americanbankingnews.com/2023/06/15/alphaq-advisors-llc-buys-new-position-in-merck-co-inc-nysemrk.html

Moderna has been working since 2019 with Merch (MRK) to develop mRNA-4157/V940, a personalized mRNA therapy.

Source: https://www.forbes.com/sites/jonmarkman/2023/05/10/modernas-revolutionary-cancer-vaccine-sets-investors-abuzz/

MRK has been the subject of several recent research reports.

Source: https://www.dailypolitical.com/2023/10/15/core-alternative-capital-reduces-holdings-in-merck-co-inc-nysemrk.html

Several research analysts have recently issued reports on MRK shares.

Source: https://www.americanbankingnews.com/2023/03/26/godsey-gibb-inc-invests-23-74-million-in-merck-co-inc-nysemrk.html